Trobix Bio is exploring utilizing its platform technology to develop new microbiome based therapeautics for numerous applications in high unmet need sectors.
“Our initial pipeline is focused on developing human therapeutic products that abolish carbapenem and ESBL resistance in gut Enterobacteriaceae. TBX101 targets the large population of patients carrying antibiotic resistant bacteria in their gut, developed as an orally available pill that will re-sensitize the gut microbiome of these patients to antibiotics.”
Trobix Bio is developiing a pipeline of innovative Microbiome based therapeutics for various oncology indications.
Trobix Bio is exploring several discovery projects to develop innovative Microbiome based therapeutics for various inflamation and immune modulation indications.
We welcome collaborations to advance the development of novel products.
For further information, please contact firstname.lastname@example.org